App-Quantinova.ai

Trial in Progress: A Phase 4 Multicenter Study of Brentuximab Vedotin Treatment in Chinese Patients with CD30-Positive Cutaneous T-Cell Lymphoma

Qian Wang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

brentuximab vedotin

Clinical Outcomes of Single-Agent Chemotherapy in a Diverse Cohort of Patients with Recalcitrant Cutaneous T-Cell Lymphoma

David M. Weiner - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Gemcitabine

Successful Restoration of Nivolumab Efficacy Post Allogeneic Stem Cell Transplantation in Hodgkin's Lymphoma

Khawlah Farhan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

brentuximab vedotin

A First in Class, Open-Label, First-in-Human, Phase I Trial of Daily Oral Pclx-001

Randeep Sangha - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

N/A

Trial in Progress: Zanubrutinib with Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial with a Safety Lead-in

Yuliya Linhares - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Solid malignancies

Temozolomide

Prevalence of Cancer & Cancer Subtypes and Association with Benzene, Toluene, Ethylbenzene, and Xylene - a Study from the National Health and Nutrition Survey

Arsh Chowdhary - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Expression Signature and Prognostic Value of BCL2 Translocation for Diffuse Large B-Cell Lymphoma Patients in China

Yan Qin - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

EP300

Low Incidence of Fungal Infections after Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma in an Endemic Region for Coccidioidomycosis

Charles Gaulin - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

N/A

Castleman Disease: A Population Based Study Using the National Cancer Institute's Surveillance, Epidemiology, and End Results Program

Kripa Ahuja - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

N/A

The Incidence, Risk Factors and Predictive Nomograms for Early Death of Elderly Patients with Diffuse Large B-Cell Lymphoma

Lingke Zhang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Efficacy Analysis of Bruton's Tyrosine Kinase Inhibitor Combined Regimen in the Treatment of Elderly Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

Wenyu Shi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

L-Tyrosine

Real-World Analysis of Cytopenias after Chimeric Antigen Receptor T-Cell Therapy: A Comparison of BCMA and CD19 Based Outcomes

Tony Z. Zhuang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab Plus Bendamustine in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Single Center Analysis of Pola Compassionate Use Program (CUP) in China

Tao Yang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

Solid malignancies

Polatuzumab vedotin

Initiation and Implementation of Infusional Chemotherapy As a Base Regimen for Increased Risk Lymphoid Malignancy in an Inner-City Academic Institution

Walter JR Quan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cyclophosphamide

Localized Nodal Diffuse Large B Cell Lymphoma: Is Radiotherapy Needed?

Anita C. Cortez - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Autologous Stem Cell Transplantation (ASCT) Improves Survival Outcome in Primary Central Nervous System Lymphoma (PCNSL) in a Minority Rich, Underserved Inner City Population in the Real-World Setting

Hiba Narvel - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methotrexate

Lysosome Dysfunction Contributes to Myeloproliferative Neoplasm Development Via Oncostatin-M Dependent Inflammation

Hyundong Yoon - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Solid malignancies

oncostatin-M

Liver Toxicity As Dose Limiting Toxicity of Bosutinib in Combination with Atezolizumab in Chronic Myeloid Leukemia. Results from the Phase Ib/II Zerolmc Trial

Valentin Garcia Gutierrez - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Atezolizumab

Immunological Response to Sars-Cov-2 after Infection and/or Vaccination Among Chronic Myeloid Leukemia Patients - a Prospective Study

Marisol Miranda - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Real World Outcomes of Chronic Myeloid Leukemia in Era of Tyrosine Kinase Inhibitors a Single Center Experience

Seema G Naik - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

L-Tyrosine

Filters

41730 Abstracts